Sequoia Financial Advisors LLC Sells 2,327 Shares of Elevance Health, Inc. $ELV

Sequoia Financial Advisors LLC cut its position in Elevance Health, Inc. (NYSE:ELV) by 26.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,625 shares of the company’s stock after selling 2,327 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in Elevance Health were worth $1,939,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Sei Investments Co. increased its stake in shares of Elevance Health by 7.7% in the second quarter. Sei Investments Co. now owns 163,668 shares of the company’s stock worth $63,666,000 after purchasing an additional 11,745 shares during the period. Glenview Trust co boosted its stake in Elevance Health by 41.5% during the 2nd quarter. Glenview Trust co now owns 1,619 shares of the company’s stock valued at $630,000 after purchasing an additional 475 shares during the period. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main boosted its stake in Elevance Health by 6.9% during the 2nd quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 65,945 shares of the company’s stock valued at $25,650,000 after purchasing an additional 4,272 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Elevance Health by 5.0% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 42,371 shares of the company’s stock valued at $16,478,000 after buying an additional 2,012 shares during the last quarter. Finally, Quantinno Capital Management LP increased its position in Elevance Health by 111.8% in the 2nd quarter. Quantinno Capital Management LP now owns 43,911 shares of the company’s stock worth $17,080,000 after buying an additional 23,180 shares during the period. Institutional investors own 89.24% of the company’s stock.

Insider Transactions at Elevance Health

In related news, Director Robert L. Dixon, Jr. sold 151 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $401.77, for a total value of $60,667.27. Following the completion of the transaction, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This represents a 1.39% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.34% of the stock is owned by company insiders.

Elevance Health Stock Performance

Shares of NYSE ELV opened at $389.85 on Thursday. The firm has a market capitalization of $84.66 billion, a price-to-earnings ratio of 16.58, a PEG ratio of 2.42 and a beta of 0.67. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $436.24. The business has a fifty day simple moving average of $399.67 and a 200 day simple moving average of $355.07. The company has a current ratio of 1.48, a quick ratio of 1.48 and a debt-to-equity ratio of 0.70.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, topping analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The firm had revenue of $49.83 billion for the quarter, compared to the consensus estimate of $48.88 billion. During the same quarter in the previous year, the company earned $8.84 earnings per share. The business’s revenue was up .8% compared to the same quarter last year. Sell-side analysts expect that Elevance Health, Inc. will post 26.86 EPS for the current year.

Elevance Health Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be paid a $1.72 dividend. The ex-dividend date of this dividend is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s payout ratio is presently 29.26%.

Elevance Health News Summary

Here are the key news stories impacting Elevance Health this week:

• Positive Sentiment: Elevance Health beat Q2 estimates, reporting EPS of $7.45 versus $6.18 expected and revenue of $49.83 billion versus $48.84 billion projected. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
• Positive Sentiment: The company raised its 2026 adjusted EPS guidance to at least $27.00, suggesting management expects improved operating performance and better medical cost control ahead. Elevance raises annual profit forecast on better medical cost management
• Positive Sentiment: Management said results were supported by disciplined execution, improved operating performance, and lower medical costs in some plans, which could help margins recover. Elevance Health Profits Eclipse $1.4 Billion As Costs Ease Somewhat
• Neutral Sentiment: Elevance also announced a quarterly dividend of $1.72 per share, reinforcing its shareholder-return profile. MarketBeat dividend notice
• Negative Sentiment: Despite the beat, the stock is being pressured by margin concerns, including a higher benefit-expense ratio and ongoing cost pressure in parts of the business. Elevance Health Raises Earnings Outlook on Higher Sales
• Negative Sentiment: Year-over-year EPS fell from $8.84, and softer membership plus higher expenses suggest earnings momentum is not yet fully stable. ELV Beats Q2 Earnings Estimates on Higher CarelonRx Product Revenues

Wall Street Analyst Weigh In

A number of research analysts have recently commented on ELV shares. Wall Street Zen lowered Elevance Health from a “buy” rating to a “hold” rating in a report on Sunday. JPMorgan Chase & Co. raised their price objective on shares of Elevance Health from $411.00 to $476.00 and gave the stock an “overweight” rating in a research note on Monday, June 8th. Weiss Ratings upgraded shares of Elevance Health from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, May 18th. Robert W. Baird increased their price target on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a report on Thursday, April 23rd. Finally, Jefferies Financial Group dropped their price objective on shares of Elevance Health from $395.00 to $391.00 and set a “buy” rating on the stock in a report on Monday, April 20th. Fifteen investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $435.05.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.